Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj ...

Today, OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an ...

The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...

Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...

BOULDER, Colo.--(BUSINESS WIRE)--Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) testing, today announced the presentation of multiple studies showcasing Foresight ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

MRD detection is the future — allowing us to monitor patients in real-time. The data is strong and we're excited that our approach can now be incorporated into future studies." Dr. Roy Herbst, study's ...

Using the newly created MAESTRO-Pool tool, whole genome sequencing revealed DNA that could be used to more effectively detect minimum residual disease (MRD) in patients who have diffuse large B-cell ...

We hypothesized that circulating tumor DNA (ctDNA) molecular residual disease (MRD) analysis without prior mutational knowledge could be performed after neoadjuvant chemotherapy to assess ...